WGS - NASDAQ
GeneDx Holdings Corp.
$55.75
+5.2%GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
At a Glance
Live Snapshotwgs
Selling, General and Administrative Expenses
Last Annual Value
239.22M
3-Year CAGR
-11%
5-Year CAGR
8%
10-Year CAGR
13%
GeneDx Holdings Corp. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 GeneDx Holdings Corp. NASDAQ:WGS | 239.22M | 7.1% | -5.6% | N/A | |
 Privia Health Group, Inc. NASDAQ:PRVA | 165.29M | 7.2% | -9.9% | N/A | |
 NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | 106.30M | 41.4% | 79.7% | N/A | |
 Kymera Therapeutics, Inc. NASDAQ:KYMR | 68.20M | 7.4% | 13.4% | N/A | |
 Hinge Health, Inc. NYSE:HNGE | 646.46M | 44.4% | N/A | N/A | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 48.39M | 9.3% | 35.2% | 25.9% | |
 Oscar Health, Inc. NYSE:OSCR | 2.05B | N/A | 50.5% | N/A | |
 Immunovant, Inc. NASDAQ:IMVT | 76.24M | 16.7% | 14.0% | N/A | |
 TransMedics Group, Inc. NASDAQ:TMDX | 185.17M | 15.7% | 37.1% | 36.7% | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 191.33M | 48.8% | 50.8% | 62.0% | |
 Option Care Health, Inc. NASDAQ:OPCH | 682.45M | 4.0% | 5.4% | 33.2% |
GeneDx Holdings Corp. Fair Value Envelope
Related Guides
Continue your WGS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.